I looked at the article "BET Bromodomain Inhibition Promotes Anti-tumor Immunity by Suppressing PD-L1 Expression" and in it they indicate that "As JQ1 is clinically applicable (known as TEN-010 in clinical trials), we performed further validation on this inhibitor." However, from another abstract, they indicate "TEN-010 is structurally related to JQ1 with superior chemical and biological properties currently under clinical study study solid tumors, including NMC, and hematologic malignancies." So TEN-010 is a JQ1 like analog. Tensha developed TEN-010, but then Tensha was acquired by Roche. On Roche's pipeline page, this drug is now listed as RG6146. TEN-010 doesn't seem to be orally available and in one of the two trials listed on clinicaltrials.gov, it explicitly indicates they were using subcutaneous dosing. TEN-010 has been in clinical trials since 2013. It is likely one of the original first-generation BET inhibitor scaffolds. The trials currently indicate that their estimated primary completion dates are June 2017 and August 2017. ZEN-3694, and probably the entire BET inhibitor libraries of Resverlogix and Zenith, are based on improved scaffolds and are orally available.